Richard Lipton (Albert Einstein College of Medicine) discusses his recently published article, with co-authors Merle Diamond and Stewart Tepper, entitled: Expert Perspectives—Migraine Prevention for Highly Impacted Patients. In this review, they discuss the burden of migraine, barriers to the use of preventive treatments, and current and emerging approaches to treating migraine in highly impacted patients. The full article can be viewed here.
1. What characteristics of a patient are highly impacted by migraine? (0:11)
2. What are the barriers that you see that keep patients from receiving benefit on current preventative therapies? (1:29)
3. What is your treatment approach for these patients and what novel therapies are on the horizon that will add to your treatment armamentarium? (3:35)
Speaker disclosures: Richard B Lipton receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (Pl), RO1 NS082432 (Investigator), 1 RF1 AG057531 (Site Pl), RF1 AG054548 (Investigator), 1 RO1 AG048642 (Investigator), R56 AG057548 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor), 1 K01AG054700 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology, is senior advisor to Headache, and associate editor to Cephalalgia. He has reviewed for the NIA and NINOS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy's, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff's Headache 7th and 8th Edition, Oxford Press University, 2009, Wiley and lnforma.
Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018, with support from Alder BioPharmaceuticals.